Необязательная аналитика продукта
С вашего разрешения мы используем ограниченную аналитику с защитой конфиденциальности, чтобы понять, какие исследовательские сценарии работают. Мы не используем рекламные трекеры или запись сеансов. Этот выбор можно изменить в настройках. Прочитайте Политику конфиденциальности.
Viatris Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $20.3B | |
|---|---|---|
| P/E (forward) | 6.4x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $17.81B | $16.22B | $15.39B | $14.69B | $14.25B | -5.4% |
| Gross profit | $5.58B | $6.50B | $6.44B | $5.62B | $5.01B | -2.6% |
| Operating income | $-34.0M | $1.61B | $766.2M | $10.1M | $-2.66B | — |
| Net income | $-1.27B | $2.08B | $54.7M | $-634.2M | $-3.51B | — |
| EPS (diluted) | $-1.05 | $1.71 | $0.05 | $-0.53 | $-3.00 | — |
| EBITDA | $4.48B | $6.43B | $3.52B | $2.64B | $-395.4M | — |
| R&D | $751.1M | $662.2M | $805.2M | $808.7M | $965.9M | +6.5% |
| SG&A | $4.53B | $4.18B | $4.07B | $4.10B | $3.79B | -4.3% |
Recent company headlines from major financial publishers.
The Base case assumes Viatris executes on management guidance of ~2% operational revenue growth, achieving over 100 new product approvals while maintaining operating margins around 16.5% to 18.5%. Operating cash flow of approximately $2.3B supports ongoing debt reduction, yielding a Fair value of $15.91.
The Bull case envisions accelerated commercialization of complex generics and specialty pipeline assets, such as meloxicam reaching peak sales potential up to $500M. Operating margins expand substantially and rapid deleveraging drives multiple re-rating toward peer levels.
| Ke ↓ / g → | 1.5% | 1.8% | 2.0% | 2.3% | 2.5% |
|---|---|---|---|---|---|
| 8.1% | $16.5 | $16.5 | $16.5 | $16.5 | $16.5 |
| 8.6% | $16.2 | $16.2 | $16.2 | $16.2 | $16.2 |
| 9.1% | $15.9 | $15.9 | $15.9 | $15.9 | $15.9 |
| 9.6% | $15.6 | $15.6 | $15.6 | $15.6 | $15.6 |
| 10.1% | $15.3 | $15.3 | $15.3 | $15.3 | $15.3 |
Upcoming earnings date and setup when available.
Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.
| Год | янв. | февр. | март | апр. | май | июнь | июль | авг. | сент. | окт. | нояб. | дек. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
